-
1
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 252-264
-
-
Pardoll, D.M.1
-
3
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ etal. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
-
4
-
-
84920956735
-
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
-
Herbst RS, Soria JC, Kowanetz M etal. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567.
-
(2014)
Nature
, vol.515
, pp. 563-567
-
-
Herbst, R.S.1
Soria, J.C.2
Kowanetz, M.3
-
5
-
-
80052476869
-
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
-
Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28: 682-688.
-
(2011)
Med Oncol
, vol.28
, pp. 682-688
-
-
Mu, C.Y.1
Huang, J.A.2
Chen, Y.3
Chen, C.4
Zhang, X.G.5
-
6
-
-
84873666114
-
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study
-
Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study. Tumori 2012; 98: 751-755.
-
(2012)
Tumori
, vol.98
, pp. 751-755
-
-
Chen, Y.B.1
Mu, C.Y.2
Huang, J.A.3
-
7
-
-
61549122071
-
Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma
-
Gao Q, Wang XY, Qiu SJ etal. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15: 971-979.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 971-979
-
-
Gao, Q.1
Wang, X.Y.2
Qiu, S.J.3
-
8
-
-
84878962707
-
PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer
-
Song M, Chen D, Lu B etal. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS ONE 2013; 8 (6): e65821.
-
(2013)
PLoS ONE
, vol.8
, Issue.6
, pp. e65821
-
-
Song, M.1
Chen, D.2
Lu, B.3
-
9
-
-
84897404380
-
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
-
Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014; 50: 1361-1369.
-
(2014)
Eur J Cancer
, vol.50
, pp. 1361-1369
-
-
Yang, C.Y.1
Lin, M.W.2
Chang, Y.L.3
Wu, C.T.4
Yang, P.C.5
-
10
-
-
84891534246
-
Programmed death ligand-1 expression in non-small cell lung cancer
-
Velcheti V, Schalper KA, Carvajal DE etal. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94: 107-116.
-
(2014)
Lab Invest
, vol.94
, pp. 107-116
-
-
Velcheti, V.1
Schalper, K.A.2
Carvajal, D.E.3
-
11
-
-
84874942318
-
Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
-
Kobayashi K, Hagiwara K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol 2013; 8: 27-33.
-
(2013)
Target Oncol
, vol.8
, pp. 27-33
-
-
Kobayashi, K.1
Hagiwara, K.2
-
12
-
-
32944472874
-
B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer
-
Simon I, Zhuo S, Corral L etal. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 2006; 66: 1570-1575.
-
(2006)
Cancer Res
, vol.66
, pp. 1570-1575
-
-
Simon, I.1
Zhuo, S.2
Corral, L.3
-
13
-
-
84901466325
-
Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications
-
Zheng ZX, Bu ZD, Liu XJ etal. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res 2014; 26: 104-111.
-
(2014)
Chin J Cancer Res
, vol.26
, pp. 104-111
-
-
Zheng, Z.X.1
Bu, Z.D.2
Liu, X.J.3
-
14
-
-
84920655625
-
PD-L1 and PD-1 expression in molecularly selected non-small cell lung cancer patients
-
D'Incecco A, Andreozzi M, Ludovini V etal. PD-L1 and PD-1 expression in molecularly selected non-small cell lung cancer patients. Br J Cancer 2015; 112: 95-102.
-
(2015)
Br J Cancer
, vol.112
, pp. 95-102
-
-
D'Incecco, A.1
Andreozzi, M.2
Ludovini, V.3
-
15
-
-
84923072443
-
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
-
Azuma K, Ota K, Kawahara A etal. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014; 25: 1935-1940.
-
(2014)
Ann Oncol
, vol.25
, pp. 1935-1940
-
-
Azuma, K.1
Ota, K.2
Kawahara, A.3
-
16
-
-
84890020587
-
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
-
Akbay EA, Koyama S, Carretero J etal. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 12: 1355-1363.
-
(2013)
Cancer Discov
, vol.12
, pp. 1355-1363
-
-
Akbay, E.A.1
Koyama, S.2
Carretero, J.3
|